{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:46Z","timestamp":1787120866596,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic myeloid leukemia (CML) is a highly controllable cancer after the introduction of BCR-ABL tyrosine kinase inhibitors (TKIs). However, in real-world settings, there is limited evidence on treatment response, resistance, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To measure treatment response, overall survival, and predictors of molecular response in patients with CML treated with BCR-ABL TKIs in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>This was a retrospective cohort study consisting of 650 adult patients with confirmed CML who received at least one BCR-ABL TKI between January 2023 and December 2025. All demographic, clinical, treatment, and follow-up data were abstracted from the institution\u2019s medical records. Assessment was performed for hematologic, cytogenetic, and molecular responses according to standard criteria. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan\u2013Meier analysis, and predictors of response and survival were identified using multivariable regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age was 49.8\u202f\u00b1\u202f14.2\u202fyears, and 57.8% were male. The majority of patients were seen in the chronic phase (91.1%). Complete hematologic response, complete cytogenetic response, major molecular response (MMR) and deep molecular response (DMR) were observed in 93.4, 83.4, 76.3 and 48.9% of patients, respectively. The second-generation TKIs had a significantly higher MMR rate than imatinib (82.9% vs. 71.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). 17.4% of patients were treatment-resistant, and 14.9% were treatment-intolerant. Three-year OS and PFS were 95.8 and 93.4%. MMR was independently predicted by younger age, chronic-phase disease, lower ELTS risk and second-generation TKIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Excellent molecular responses and favourable survival outcomes were observed among real-world patients with CML treated with BCR-ABL tyrosine kinase inhibitors. Molecular response remained an important prognostic indicator, supporting continued molecular monitoring and risk-adapted treatment. However, the available follow-up was insufficient to evaluate late-onset toxicities and longer-term treatment outcomes fully; therefore, extended follow-up studies with detailed molecular and genetic characterisation are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1905107","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:45Z","timestamp":1787118405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment response and survival outcomes with BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a retrospective study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yufen","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People\u2019s Hospital)","place":["Ganzhou, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Planning and Quality Control, Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People\u2019s Hospital)","place":["Ganzhou, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People\u2019s Hospital)","place":["Ganzhou, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41571-020-0367-1","article-title":"Treatment-free remission in patients with chronic myeloid leukaemia","volume":"17","author":"Ross","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood.2021011722","article-title":"How I treat chronic-phase chronic myelogenous leukemia","volume":"139","author":"Berman","year":"2022","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/jcm10030515","article-title":"Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: a new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12185-022-03432-7","article-title":"Asciminib as a third line option in chronic myeloid leukemia","volume":"117","author":"Lagan\u00e0","year":"2023","journal-title":"Int J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"841546","DOI":"10.3389\/fonc.2022.841546","article-title":"Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: a pairwise and Bayesian network meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1021662","DOI":"10.3389\/fonc.2022.1021662","article-title":"Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"12","author":"Yoshifuji","year":"2022","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/10781552231217694","article-title":"Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia","volume":"30","author":"Collins","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1080\/10428194.2025.2495369","article-title":"Five-year molecular response and overall survival with first-and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study\u2013SIMPLICITY","volume":"66","author":"Mauro","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41375-026-02984-5","article-title":"From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia","volume":"40","author":"Hochhaus","year":"2026","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1611497","DOI":"10.3389\/pore.2024.1611497","article-title":"Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary","volume":"30","author":"Batar","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e35963","DOI":"10.1002\/cncr.35963","article-title":"Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: data from the Italian network\/CML campus","volume":"131","author":"Giai","year":"2025","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1182\/blood.2024024657","article-title":"Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study","volume":"144","author":"Yeung","year":"2024","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11899-023-00703-w","article-title":"Real-world management of CML: outcomes and treatment patterns","volume":"18","author":"Held","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, \u2018real-world\u2019 cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.3390\/cancers17132148","article-title":"Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia","volume":"17","author":"Bourne","year":"2025","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3390\/jcm13092567","article-title":"Treatment-free remission in chronic myeloid leukemia","volume":"13","author":"Bourne","year":"2024","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3324\/haematol.2023.284860","article-title":"The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort","volume":"109","author":"Saugues","year":"2024","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","article-title":"Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance","volume":"38","author":"Claudiani","year":"2024","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.3390\/cancers14143300","article-title":"Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia","volume":"14","author":"Poudel","year":"2022","journal-title":"Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-022-00692-8","article-title":"Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network","volume":"12","author":"Sanz","year":"2022","journal-title":"Blood Cancer J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.3390\/cancers13164175","article-title":"Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors?","volume":"13","author":"Saifullah","year":"2021","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11912-022-01228-w","article-title":"Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a review of the biological factors associated with treatment-free remission","volume":"24","author":"Stuckey","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/cells12131703","article-title":"Prognosis in chronic myeloid leukemia: baseline factors, dynamic risk assessment and novel insights","volume":"12","author":"Iezza","year":"2023","journal-title":"Cells"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/ejh.70000","article-title":"Treatment-free remission in chronic myeloid leukemia: revisiting the \u201cW\u201d questions","volume":"115","author":"Bruzzese","year":"2025","journal-title":"Eur J Haematol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1905107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:46Z","timestamp":1787118406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1905107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":32,"alternative-id":["10.3389\/fmed.2026.1905107"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1905107","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1905107"}}